Biogen Idec
 
4Q Revenues: $2.6 billion (+34%)

4Q Earnings: $882.6 million (+93%)

FY Revenues: $9.7 billion (+40%)

FY Earnings: $2.9 billion (+58%)

Comments: TECFIDERA revenues were $916 million, up 130%, consisting of $743 million in U.S. sales and $173 million in sales outside the U.S. AVONEX sales were $736 million in the quarter, down 2%. PLEGRIDY sales were $41.1 million in the quarter. TYSABRI revenues were $484 million, up 13%, consisting of $266 million in U.S. sales and $218 million in sales outside the U.S. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $305 million.